Clinical Trial IDNCT04181515
Lead SponsorWayne State University
Principal Investigator
Start Date2020-07-01
Completion Date2025-06-01
Study TypeInterventional
PhasePhase 2
StatusNot yet recruiting


This study will use a stress (vs. placebo) exposure model, paired with single-session sham vs. active rTMS at two distinct cortical locations (dlPFC vs. mPFC in parallel groups) to assess whether rTMS neuromodulation at these alternative loci differentially influence stress-reactivity and opioid reinforcement in non-treatment seeking participants with OUD. Stress-reactivity will be measured using cognitive, affective, behavioral and biological phenotypes.


Stress, Opioid-use DisorderDrug: Placebo oral tablet, Drug: Yohimbine + Hydrocortisone, Device: sham rTMS, Device: active rTMSPhase 2


AgeGenderAccepts Healthy Volunteers
21 Years to 60 YearsAllNo